Analysis of 21 723 Pregnant Women's First Trimester Screening for Down Syndrome in Sichuan Province

LUO Wei, PANG Ling, HE Bin, HAN Dai-wen, LAI Yi, HU Ting, WANG He, LIU Shan-ling

Abstract

To compare the effect of different first-trimester screening programmes for Down syndrome in Sichuan Province.  Methods  We retrospectively collected the data of singleton pregnancies that were screened by serum biochemistry markers combined with nuchal translucency screening tests in the first trimester in Prenatal Diagnosis Center of West China Second University Hospital of Sichuan University from January 2011 to December 2017. The fetal chromosome results were obtained by amniocentesis or by telephone follow-up. The screening effect of maternal age, nuchal translucency thickness, maternal serum biochemistry markers and combined screening in the first trimester were analyzed.   Results  Among the 21 723 singleton pregnancies, 33 cases were diagnosed as Down syndrome, and 19 cases were diagnosed as trisomy 18 sex chromosome abnormalities were found in 4 cases, and other chromosome abnormalities were found in 8 cases. For the combined screening, the detection rate of Down syndrome was 72.73%, and the false positive rate was 2.49%; the detection rate of trisomy 18 syndrome was 73.68% with the false positive rate of 0.39%. With a 5% false positive rate, maternal age, nuchal translucency thickness, serum biochemistry markers and combined screening would respectively detect 15.15%, 57.58%, 60.61% and 87.88% of Down syndrome fetuses.   Conclusion  Compared with the other three screening programmes, the combined screening can effectively screen fetuses with Down syndrome and other chromosomal abnormalities.

 

Keywords: The first trimester screening for Down syndrome, Nuchal translucency thickness, Maternal age at expected date of delivery

 

Full Text:

PDF


References


Al-NBAHEEN M S. Analysis of Downs syndrome with molecular techniques for future diagnoses. Saudi J Biol Sci，2018，25(30): 558–562.

SAQUETTO M B， PEREIRA F F， QUEIROZ R S， et al. Effects of whole-body vibration on muscle strength bone mineral content and density, and balance and body composition of children and adolescents with Down syndrome: a systematic review. Osteoporos Int，2018，29(3): 527–533.

MALONE F D， CANICK J A， BALL R H， et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med，2005，353: 2001–2011.

SNIJDERS R J， NOBLE P， SEBIRE N， et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 11-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet，1998， 352(9125):343–346.

O’BRIEN B M， HALLIDAY J， LAMBERT M G， et al. Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA. Prenat Diagn，2017，37(3):303–305.

CAUGHEY A B， KUPPERMANN M， NORTON M E， et al. Nucal translucency and first trimester biochemical makers for down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol，2002， 187(5): 1239–1245.

CHITAYAT D， LANGLOIS S， WILSON R D， et al. No.261-Prenatal screening for fetal aneuploidy in singleton pregancies. J Obstet Gynecol Can，2017，39(9): e380–e394.

BOMSTEIN E， GULERSEN M， KRANTZ D， et al. Microarray analysis: first-trimester maternal serum free β-hCG and the risk of significant copy number variants. Prenat Digan，2018，38(12): 971–978.

Committee on Practice Bulletins—Obstetrics， Committee on Genetics， and the Society for Maternal-Fetal Medicine，ROSE N C，MERCER B M. Practice Bulletin No.163: screening for fetal aneuploidy. Obstst Gynecol， 216，127(5): e123–e137.

OZYUNCU O， TANACAN A， FADILOGLU E， et al. Impact of increased nuchal translucency values on pregnancy outcomes: a tertiary center experience. Fetal Pediatr Pathol，2019，7: 1–9.

BARD F， BOSSCHIETERP F N， VERHEIJJB G M， et al. Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening? Prenat Diagn， 2019 [2019-09-10]. https://doi.org/10.1002/pd.5590.

MONNI G， ZOPPI M A， IBBA R M， et al. Fetal nuchal translucency test for Down’s syndrome. Lancet， 1997， 350(9091): 1631[2019-09-10]. https://doi.org/10.1016/S0140-6736(05)64050-0.

ALLDRED S K， TAKWOINGI Y， GUO B， et al. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Cochrane Database Syst Rev，2017， 15(3): CD012600[2019-10-13]. https://doi.org/10.1002/14651858. CD012600.

BINDRA R， HEATH V， LIAO A， et al. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks : a prospective study of 15 030 pregnancies. Ultrasound Obestet Gynecol，2002，20: 219–225.

EKELUND C K， PETERSEN O B， JORGENSEN F S， et al. The Danish Fetal Medicine Database: establishment, organization and quality assessment of the first trimester screening program for trisomy 21 in Denmark, 2008-2012. Acta Obstet Gynecol Scand，2015，94(6): 577–583.

PARK S Y， JANG I A， LEE M A， et al. Screening for chromosomal abnormalities using combined test in the first trimester of pregnancy. Obstet Gynecol Sci，2016，59(5): 357–366.

PAN M， HAN J， YANG X， et al. A 1st-trimester combined screening test in pregnant women of advanced maternal age in a Chinese population. J Obstet Gynaecol，2015，35(2): 121–124.

BIANCHI D W， PARKER R L， WENTWORTH J， et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med， 2014，370(9): 799–808.

LAN R Y， CHOU C T， WANG P H， et al. Trisomy 21 screening based on first and second trimester in a Taiwanese population. Taiwan J Obstet Gynecol，2018，57(4): 551–554.

LI B， SAHOTA D S， LAO T T， et al. Applicability of first-trimester combined screening for fetal trisomy 21 in a resource-limited setting in mainland China. BJOG，2016，123(Suppl 3): 23–29.


Refbacks

  • There are currently no refbacks.